Latest Insider Transactions at Fulcrum Therapeutics, Inc. (FULC)
This section provides a real-time view of insider transactions for Fulcrum Therapeutics, Inc. (FULC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Fulcrum Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Fulcrum Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2024
|
Ra Capital Management, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
8,500,000
-73.21%
|
-
|
|
Jul 03
2024
|
Alex Sapir |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+43.69%
|
$450,000
$3.27 P/Share
|
|
May 07
2024
|
Greg Tourangeau Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
236
-2.0%
|
$1,652
$7.76 P/Share
|
|
Mar 08
2024
|
Greg Tourangeau Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,884
-29.26%
|
$53,724
$11.72 P/Share
|
|
Mar 04
2024
|
Alex Sapir |
BUY
Open market or private purchase
|
Direct |
43,360
+50.0%
|
$476,960
$11.35 P/Share
|
|
May 10
2023
|
Greg Tourangeau Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
210
-1.3%
|
$630
$3.31 P/Share
|
|
Jan 20
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,923,076
+14.21%
|
$24,999,988
$13.0 P/Share
|
|
Jan 13
2023
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
6,766
-1.34%
|
$101,490
$15.0 P/Share
|
|
Jan 04
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
180,703
+0.93%
|
$1,264,921
$7.42 P/Share
|
|
Dec 27
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
4,089
+0.04%
|
$20,445
$5.99 P/Share
|
|
Dec 19
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
98,787
+1.03%
|
$493,935
$5.9 P/Share
|
|
Dec 16
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,341,420
+12.48%
|
$6,707,100
$5.42 P/Share
|
|
Dec 15
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
237,029
+2.86%
|
$1,185,145
$5.5 P/Share
|
|
Dec 14
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
824,600
+9.53%
|
$4,123,000
$5.46 P/Share
|
|
Dec 13
2022
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,000,000
-50.48%
|
-
|
|
Jun 07
2022
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
71,435
-12.36%
|
$571,480
$8.09 P/Share
|
|
Jun 07
2022
|
Robert J Gould |
BUY
Exercise of conversion of derivative security
|
Direct |
71,435
+11.0%
|
$500,045
$7.84 P/Share
|
|
Jun 06
2022
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
24,382
-4.59%
|
$195,056
$8.1 P/Share
|
|
Jun 06
2022
|
Robert J Gould |
BUY
Exercise of conversion of derivative security
|
Direct |
24,382
+4.39%
|
$170,674
$7.84 P/Share
|
|
Jun 03
2022
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
25,551
-4.8%
|
$178,857
$7.95 P/Share
|
|
Jun 03
2022
|
Robert J Gould |
BUY
Exercise of conversion of derivative security
|
Direct |
25,551
+4.58%
|
$178,857
$7.84 P/Share
|
|
Jun 02
2022
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
16,689
-3.19%
|
$116,823
$7.92 P/Share
|
|
Jun 02
2022
|
Robert J Gould |
BUY
Exercise of conversion of derivative security
|
Direct |
16,689
+3.09%
|
$116,823
$7.84 P/Share
|
|
May 06
2022
|
Greg Tourangeau Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,250
+16.71%
|
-
|
|
Apr 07
2022
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
5,631
-1.1%
|
$135,144
$24.02 P/Share
|
|
Apr 07
2022
|
Robert J Gould |
BUY
Exercise of conversion of derivative security
|
Direct |
5,631
+1.09%
|
$39,417
$7.84 P/Share
|
|
Apr 05
2022
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
52,552
-9.4%
|
$1,261,248
$24.26 P/Share
|
|
Apr 05
2022
|
Robert J Gould |
BUY
Exercise of conversion of derivative security
|
Direct |
52,552
+8.59%
|
$367,864
$7.84 P/Share
|
|
Apr 04
2022
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
7,235
-1.41%
|
$173,640
$24.02 P/Share
|
|
Apr 04
2022
|
Robert J Gould |
BUY
Exercise of conversion of derivative security
|
Direct |
7,235
+1.39%
|
$50,645
$7.84 P/Share
|
|
Apr 01
2022
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
34,464
-6.37%
|
$827,136
$24.03 P/Share
|
|
Apr 01
2022
|
Robert J Gould |
BUY
Exercise of conversion of derivative security
|
Direct |
34,464
+5.99%
|
$241,248
$7.84 P/Share
|
|
Nov 10
2021
|
Mark J Levin Director |
SELL
Other acquisition or disposition
|
Indirect |
1,000,000
-20.15%
|
-
|
|
Nov 10
2021
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,000,000
-20.15%
|
-
|
|
Sep 22
2021
|
Mark J Levin Director |
SELL
Other acquisition or disposition
|
Indirect |
1,000,000
-16.77%
|
-
|
|
Sep 22
2021
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,000,000
-16.77%
|
-
|
|
Aug 11
2021
|
Bryan Stuart Director |
SELL
Open market or private sale
|
Direct |
28,000
-100.0%
|
$644,000
$23.75 P/Share
|
|
Aug 11
2021
|
Bryan Stuart Director |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+50.0%
|
$196,000
$7.84 P/Share
|
|
Aug 10
2021
|
Bryan Stuart Director |
SELL
Open market or private sale
|
Direct |
32,000
-100.0%
|
$544,000
$17.5 P/Share
|
|
Aug 10
2021
|
Bryan Stuart Director |
BUY
Exercise of conversion of derivative security
|
Direct |
32,000
+50.0%
|
$224,000
$7.84 P/Share
|
|
Aug 10
2021
|
Christopher Moxham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
31,071
-100.0%
|
$559,278
$18.0 P/Share
|
|
Aug 10
2021
|
Christopher Moxham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,785
+50.0%
|
$362,495
$7.84 P/Share
|
|
Aug 10
2021
|
Christopher Moxham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,714
-100.0%
|
$352,138
$17.0 P/Share
|
|
Jun 28
2021
|
James A Geraghty |
BUY
Open market or private purchase
|
Direct |
10,000
+9.93%
|
$90,000
$9.16 P/Share
|
|
Jun 28
2021
|
Peter G. Thomson VP Finance & Accounting |
BUY
Open market or private purchase
|
Indirect |
2,300
+50.0%
|
$20,700
$9.0 P/Share
|
|
Jun 28
2021
|
Curtis Gale Oltmans Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
1,088
+50.0%
|
$9,792
$9.01 P/Share
|
|
Jun 28
2021
|
Christopher Morabito Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,100
+50.0%
|
$9,900
$9.16 P/Share
|
|
Mar 16
2021
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
789
-0.16%
|
$9,468
$12.43 P/Share
|
|
Mar 15
2021
|
Robert J Gould |
SELL
Open market or private sale
|
Direct |
9,211
-1.78%
|
$110,532
$12.13 P/Share
|
|
Feb 22
2021
|
Peter G. Thomson VP Finance & Accounting |
SELL
Open market or private sale
|
Direct |
5,000
-24.74%
|
$70,000
$14.72 P/Share
|